Online ISSN 2313-1519
Print    ISSN 1812-2892
Abstract - Clinical and economic efficiency of multi-matrix mesalazine in ulcerative colitis treatment in the healthcare system of the Republic of Kazakhstan
Alima Almadiyeva, Venera Almatova, Timur Balabayev, Marat Sultanov, Karlygash Absattarova


Aim: Clinical and economic evaluation of multi-matrix mesalazine 1200 mg compared with prolonged-release mesalazine at a dose of 500mg for the treatment of patients aged 18 years and older with the diagnosis of ulcerative colitis in the phase of exacerbation and remission.

Material and methods: In accordance with the PICOS tool all published literature sources were identified in the electronic resources PubMed/Medline, DARE, Cochrane Central Register of Controlled Trials; the analysis included 5 studies with levels of evidence A and B. Calculations were performed in STATA and Microsoft Excel 10.0

Results and discussion: According to the results of clinical and economic analysis, the strategy of using multi-matrix mesalazine is dominant in comparison with prolonged-release mesalazine as a first-line therapy and contributes to the increment of efficiency and leads to the minimization of costs to achieve a QALY unit per patient. Patients receiving multi-matrix mesalazine have a longer duration of remission and less likelihood of re-exacerbations.

Conclusion: The use of multi-matrix mesalazine in comparison with prolonged-release mesalazine is an economically feasible alternative in the conditions of health care of the Republic of Kazakhstan – more effective and less financially costly, leading to potential budget savings.

Key words: multi-matrix mesalazine, non-specific ulcerative colitis, Crohn's disease, efficacy, QALY

Corresponding Author: Karlygash Absattarova, Public Healthcare Department, Kazakhstani Agency on Healthcare Technologies Assessment, Astana city, Republic of Kazakhstan. E-mail:



1. Burisch, J., & Munkholm, P. The epidemiology of inflammatory bowel disease. Scandinavian Journal of Gastroenterology. 2015; 50(8):942-951.

2. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012; 10:CD000543.

3. Feagan BG, et al. Are there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from cochrane reviews. Inflamm Bowel Dis. 2013; 19:2031-2040.

4. Prenzler A, et al. Cost effectiveness of ulcerative colitis treatment in Germany: A comparison of two oral formulations of mesalazine. BMC Health Services Research. 2011; 11.

5. Nishikawa A. M., Paladini L., Delfini R., Kotze P. G., Clark O. Decision tree construction and cost-effectiveness analysis of treatment of ulcerative colitis with pentasa ® mesalazine 2 g sachet. Arquivos de Gastroenterologia. 2013; 50(4):297-303.

6. Yen, E. F., et al. Cost-Effectiveness of 5-Aminosalicylic Acid Therapy for Maintenance of Remission in Ulcerative Colitis. The American Journal of Gastroenterology. 2008; 103(12):3094-3105.

7. Brereton N, et al. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. Journal of Medical Economics. 2010; 13(1):148-61.

8. Buckland A., Bodger K. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. Alimentary Pharmacology & Therapeutics. 2008; 28(11-12):1287-1296.

9. Saini S. D., et al. Cost Utility of Inflammation-Targeted Therapy for Patients with Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2012; 10(10):1143-1151.

10. Connolly MP, et al. The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands. Netherlands Journal of Medicine. 2012; 70(6):272-7.

11. Tappenden P, Ren S, Archer R, Harvey R, James MM, Basarir H, et al. A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. Pharmacoeconomics. 2016; 34(10):1023-38.

12. J. P. Gisbert, F. et al. Evaluación de coste-efectividad mediante análisis teórico de minimización de costes del uso de dos mesalazinas gastrorresistentes de liberación prolongada en el manejo de la colitis ulcerosa. en España Gastroenterología y Hepatología, 2016; 39(3):199-212

13. Kruis W, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut. 2009; 58:233-240.

14. G.R. D'Haens, et al. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2017; 1-11.

15. Lichtenstein GR, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderate active ulcerative colitis. Clin Gastroenterol Hepatol. 2007; 5:95-102.

16. Flourie B, et al. Randomised clinical trial: once- vs twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther. 2013; 37:767-775.

17. Kamm MA, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008; 57:893-902.

18. Scott D. et al. Good Research Practices for Cost-Effectiveness Analysis alongside Clinical Trials. The ISPOR RCT-CEA Task Force Report. Value in Health. 2005; 8,:521-533.

19. Prikaz Ministra zdravoohranenija i social'nogo razvitija RK ot 16 sentjabrja 2015 goda № 725 «Ob utverzhdenii tarifov na medicinskie uslugi v ramkah rekomendacij klinicheskogo protokola diagnostiki i lechenija «Jazvennyj kolit» (odobrennogo protokol'nym resheniem № 23 Ob#edinennoj komissiej po kachestvu medicinskih uslug MZ RK ot 25maja 2017 goda) [in Russian].язвенный-колит/15033

20. Ministerstvo nacional'noj jekonomiki RK. Komitet po statistike. Dinamika osnovnyh social'no-jekonomicheskih pokazatelej. [in Russian]. Dostupno na

21. Schroeder K. W., Tremaine W. J., Ilstrup D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317:1625-1629.

22. Ko, C.W., Singh, S., Feuerstein, J.D., Falck-Ytter, C., Falck-Ytter, Y., Cross, R.K. American Gastroenterological Association Institute Guideline on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology. 2019; 156(3):748-764.

23. Valovoi vnutrennii product na dushu naseleniya. Kommitet po statistike Ministerstva natsionalnoi ekonomiki RK. Dostupno na

24. Matsuoka K., Kobayashi T., Oeno F., Matsui T., Hirai F., Inoue N., Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018; 53(3):305-353

25. Robinson A, Hankins M, Wiseman G, Jones M. Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse. Aliment Pharmacol Ther. 2013; 38:53-538

26. Danese S, Banerjee R, Cummings JF, et al. Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. Intest Res. 2018; 16(4):522-528.

27.Jeon SR. Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis? Intest Res. 2018; 16(2):163-165.

28. Ogata H, Yokoyama T, Mizushima S, Hagino A, Hibi T. Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study. Intest Res. 2018;16(2):255-266.


Volume 2, Number 52 (2019)